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Abstract
We previously observed a substantial burden of cryptococcal meningitis in Vietnam atypically arising in in-
dividuals who are uninfected with human immunodeficiency virus (HIV). This disease was associated with a
single genotype of Cryptococcus neoformans (sequence type [ST]5), which was significantly less common
in HIV-infected individuals. Aiming to compare the phenotypic characteristics of ST5 and non-ST5 C. neofor-
mans, we selected 30 representative Vietnamese isolates and compared their in vitro pathogenic potential
and in vivo virulence. ST5 and non-ST5 organisms exhibited comparable characteristics with respect to in
vitro virulence markers including melanin production, replication at 37°C, and growth in cerebrospinal fluid.
However, the ST5 isolates had significantly increased variability in cellular and capsular sizing comparedwith
non-ST5 organisms (P < .001). Counterintuitively, mice infected with ST5 isolates had significantly longer
survival with lower fungal burdens at day 7 than non-ST5 isolates. Notably, ST5 isolates induced significantly
greater initial inflammatory responses than non-ST5 strains, measured by TNF-α concentrations (P < .001).
Despite being generally less virulent in the mouse model, we hypothesize that the significant within strain
variation seen in ST5 isolates in the tested phenotypes may represent an evolutionary advantage enabling
adaptation to novel niches including apparently immunocompetent human hosts.
Key words: Cryptococcal meningitis, Cryptococcus neoformans, immunocompetent, HIV, virulence.
Introduction
Cryptococcal meningitis (CM) is a life-threatening fungal in-
fection caused principally by Cryptococcus neoformans and
Cryptococcus gattii.1–3 Despite CM being more common in
immunocompromised patients, CM can also arise in appar-
ently immunocompetent patients. Recent figures estimate an an-
nual global CM incidence of 223,100 cases in patients infected
with human immunodeficiency virus (HIV), resulting in 181,100
deaths.4
Generally, C. gattii is the most common cause of CM in im-
munocompetent patients, while C. neoformans is primarily re-
sponsible for disease in immunocompromised patients.5 When
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CM associated with C. neoformans var. grubii occurs in HIV-
uninfected individuals, reports often describe patients with an
increased susceptibility due to other underlying immunosuppres-
sive conditions.6,7 In Vietnam, C. neoformans var. grubii CM
in HIV-uninfected patients accounts for approximately 20% of
all CM cases admitted to our hospital in Ho Chi Minh City
(HCMC).8 We previously reported that the majority of HIV-
uninfected CM patients had no identified cause or other med-
ical history suggestive of immunosuppression, and that >80%
of HIV-uninfected CM patients were infected by a single geno-
type of C. neoformans var. grubii,9 which we later confirmed to
be Sequence Type 5 (ST5).
Our clinical observations have been replicated in China,
where >70% of CM cases from apparently immunocompetent
individuals were infected with C. neoformans.10,11 Again, these
organisms were later identified as genotype ST5.12,13 Compara-
bly, ST5 accounted for >80% of HIV-uninfected CM patients in
South Korea, although some patients from this location had po-
tentially immunosuppressive conditions.14 This association be-
tween a ST and host immune phenotype could be explained by
lineage-specific increases in pathogenic potential, fitness in the
human host, an unidentified host immune deficit, or a combi-
nation of these three factors. Recent high-resolution genomic
investigation of the population structure of clinical C. neofor-
mans var. grubii isolates has verified that ST5 and ST4 are ge-
netically distinct lineages of C. neoformans var. grubii, namely,
VNIa-5 and VNIa-4, and that VNIa-5 is most frequently iso-
lated from Asia, although it has been isolated from human clin-
ical specimens in east and southern Africa, Europe, and the
USA.15
Here, in order to explore the hypothesis that C. neoformans
var. grubii ST5 have an increased pathogenic potential in com-
parison to non-ST5 organisms, we compared their in vitro vir-
ulence phenotypes and exploited an established cryptococcosis
mouse model to compare their relative pathogenicity and ability
to induce systemic inflammation.
Methods
C. neoformans isolates and culture conditions
We used clinical isolates obtained at the point of diagnosis,
prior to antifungal therapy, from the cerebrospinal fluid (CSF)
of patients enrolled in a prospective descriptive study of HIV-
uninfected patients with central nervous system (CNS) infec-
tions, and a randomized controlled trial of antifungal therapy in
HIV-infected patients.8,16 We randomly selected 15 isolates from
HIV-uninfected CM patients and 15 from HIV-infected CM pa-
tients.MLST profiles (CAP59,GPD1, IGS1, LAC1, PLB1, SOD1,
URA5) for all isolates were previously determined.17 C. neo-
formans yeasts were propagated using yeast peptone dextrose
(YPD) broth and incubated overnight at 30°C with agitation.
Isolates and clinical information from corresponding patients are
summarized in Table 1.
Growth at human host temperature, in ex vivo
human CSF and melanin production
Growth at 37°C and in ex vivo human CSF were tested as
previously described18 with modifications for quantitative as-
sessment. To assess fungal growth at different temperatures,
the inoculum was adjusted to 108 cells/ml, serially diluted
and spot-inoculated in duplicate on YPD agar in 5 μl aliquots
and incubated at 30°C or 37°C for 48 hours. After 48 hours,
colony-forming units (cfu were counted and recorded in cfu/ml).
For the ex vivo CSF growth assay, baseline preantifungal
treatment CSF supernatant from random de-identified HIV-
infected patients enrolled into an antifungal therapy trial was
pooled, filtered, and stored at -80°C until use. 10 µl of
108 cells/ml yeast suspension was inoculated into 90 µl of
pooled CSF and incubated at 37°C with 5%CO2. Inoculated
CSF was serially diluted and spotted on YPD agar at days 1
and 3 postinoculation. All experiments were repeated in trip-
licate. The H99-derived mutant ena1, which lacks a cation-
ATPase-transporter resulting in decreased viability in human
CSF and macrophages, was used as a negative control for
the ex vivo CSF assay.19 H99 was included as a reference
in all experiments. Data were standardized by expressing the
results as a ratio of the cfu/ml of the test isolate to the
cfu/ml of H99. Melanin production was assessed by plating
5 μl of 106cells/ml cell suspension on L-DOPA agar contain-
ing 1 g/l L-asparagine, 1 g/l glucose, 3 g/l KH2PO4, 250 mg/l
MgSO4.7H2O, 1 mg/l Thiamine HCl, 5 μg/l Biotin, 100 mg/l
L-DOPA, 20 g/l Bacto Agar.20,21 Plates were incubated in
the dark at 30°C or 37°C for 3 days. Differences in colony
melanization were compared visually with reference to H99
and an H99-derived mutant with diminished melaninization in
L-DOPA agar from the Perfect lab.
Extracellular urease and phospholipase activity
Extracellular urease production was semiquantified using Chris-
tensen’s agar. And 10 μl of 108 cells/ml yeast suspension was
spotted on Christensen’s agar and incubated at room temper-
ature. The time to complete plate coloration was determined
using a GoPro Hero 6 camera (Gopro, San Mateo, CA, USA)
using the time-lapse setting set with a 1-minute interval. C.
neoformans H99 was used as a positive control and Candida
albicans as a negative control. Extracellular phospholipase ac-
tivity was screened on egg yolk medium as previously described,
with minor modifications.22 The egg yolk medium contained
Sabouraud agar with 1 M sodium chloride, 0.005 M calcium
chloride and 8% sterile egg yolk enrichment (Merck, USA). A
5 µl aliquot ofC. neoformans yeast suspension (108 cells/ml) was
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Table 1. Cryptococcus neoformans isolate clinical source and typing (n = 30).
Isolate data Patient data
Order Strain name WGS cluster MLST sequence type Underlying Disease Sex
1 BK14 VNIa-4 4 HIV M
2 BK163 VNIa-4 4 HIV M
4 BK225 VNIa-4 4 HIV M
6 BK48 VNIa-4 4 HIV M
7 BK59 VNIa-4 4 HIV F
8 BK69 VNIa-4 4 HIV M
9 BK74 VNIa-4 4 HIV M
10 BK80* VNIa-4 4 HIV M
11 BK87 VNIa-4 4 HIV M
12 BK88 VNIa-4 4 HIV M
13 BK89 VNIa-4 4 HIV M
15 BMD1415* VNIa-4 4 Lupus M
3 BK218 VNIa-4 6 HIV M
5 BK234 VNIa-4 6 HIV F
14 BMD1367* VNIa-4 306 Gastric cancer F
16 BK147* VNIa-5 5 HIV M
17 BK44* VNIa-5 5 HIV M
18 BMD101 VNIa-5 5 None known M
19 BMD1228 VNIa-5 5 None known F
20 BMD1291 VNIa-5 5 None known F
21 BMD1338* VNIa-5 5 None known M
22 BMD1353 VNIa-5 5 None known M
23 BMD1452 VNIa-5 5 None known F
24 BMD1646* VNIa-5 5 None known M
25 BMD1716 VNIa-5 5 None known F
26 BMD367 VNIa-5 5 None known M
27 BMD673 VNIa-5 5 None known F
28 BMD700* VNIa-5 5 None known M
29 BMD854 VNIa-5 5 None known F
30 BMD899 VNIa-5 5 None known F
WGS = whole genome sequencing.
MLST = multi locus sequence typing.
M = Male, F = Female.
* Indicates isolates selected for mouse experiment.
spotted on egg yolk agar and incubated at 30°C for 72 hours.
The diameters of the precipitation zone (D) formed around
the colonies and of the respective colonies (d) were recorded
after 72 hours incubation. The D/d ratio for each isolate was
calculated. H99 was included for reference in each experimental
batch. The final result for each isolate was expressed as the ratio
between the test isolate’s D/d ratio and that of H99. All isolates
were tested in triplicate for each phenotype.
In vitro capsule and cell size measurement
To measure in vitro cryptococcal capsule thickness, all iso-
lates were streaked onto capsule-inducing agar containing pow-
dered Dulbecco Modified Eagle Medium (DMEM) (supple-
mented with 4.5 g/l glucose, L-glutamine, sodium pyruvate),
NaHCO3 250 mM, NaMOPS 1 M, Neomycin 200 mg/ml, Ce-
fotaxime 100 mg/ml.23 Plates were incubated at 37°C in 5%
CO2 until single colonies were visible. Unless otherwise speci-
fied, all reagents were purchased from Sigma-Aldrich. India ink
smears from a single yeast colony were prepared on a glass slide
and visualized at 100× magnification using a CX41 microscope
(Olympus, Shinjuku, Japan). Images of single microscopic yeast
cells were captured using a DP71 Camera system with DP Con-
troller software (Olympus, Japan) and processed using ImageJ
(rsb.info.nih.gov/ij/). Capsular thickness was calculated by sub-
tracting yeast cell body diameter (DCD, no capsule) from whole
cell diameter (DWC, including capsule). At least 30 individual mi-
croscopic yeast cells were assessed for each isolate.
Mouse inhalation infection model of cryptococcosis
All mouse infection experiments were conducted as previ-
ously described according to Duke University’s Institutional
Animal Care and Use Committee guidelines and approvals.24
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Six-week-old female A/J mice were sedated with isoflurane and
inoculated intranasally with the selected C. neoformans var.
grubii isolate by dropping 25 µl of yeast suspension containing
5 × 104 cells into the nares. Eight isolates were randomly
selected from the 30 for murine experiments. The isolates were
five ST5 (BK147 and BK44 from HIV-infected patients and
BMD700, BMD1338, and BMD1646 from HIV-uninfected
patients) and three non-ST5 strains (BMD1415 (ST4) and
BMD1367 (ST306) from HIV-uninfected patients and BK80
(ST4) from an HIV-infected patient). Animals were monitored
daily and euthanized by CO2 inhalation at indicated time points
(fungal burden and in vivo responses) or until weight loss ≥15%
body weight was observed (virulence assay).
Determining in vivo fungal burden
Five mice were infected with each isolate in two independent
experiments for assessment of fungal burden at 7- or 14-days
postinfection. All animals in each experiment set were eutha-
nized by CO2 inhalation either on day 7 or day 14 postinfection.
Fungal burden at each time point was assessed by excising the
left superior lobe of the lung and brain and homogenizing the tis-
sue by bead beating. Tissue homogenate was serially diluted and
plated onto YPD agar supplemented with 100 mg/ml ampicillin.
The plates were incubated at 30°C for 48 hours, and the num-
ber of C. neoformans cfu were recorded. Fungal burdens were
expressed as cfu per gram of tissue (cfu/g). At each time point,
additional lung lobes were also collected for determining in vivo
histopathology and cytokine response, as described below. In ad-
dition, fungal burdens were separately determined at the point of
death in animals from the survival assays described below.
Determining in vivo histopathology
At specific time points (7 or 14 days postinfection, as described
above), the right superior lung lobe from eachmouse was excised
and immersed in 10% formalin (replaced with 70% ethanol af-
ter 24 hours) for fixation. Fixed, uninflated lung specimens were
stored at 4°C until further processing. After paraffin embedding,
sliced sections were stained using the periodic acid-Schiff (PAS)
or mucicarmine stains. Histopathological examination was per-
formed by an independent pathologist blinded to infecting strain.
Tissue damage was scored from 0 (no changes) to 10 (severe
changes), corresponding to the severity of pathology in four dif-
ferent categories: necrosis, hemorrhage, edema, and inflamma-
tion, as per the Duke Veterinary Diagnostic Laboratory (Division
of Laboratory Animal Resources).
Determining in vivo cytokine response
To assess the severity of the inflammatory responses at specific
time points (day 7 and day 14 postinfection), the middle lobe
from the right lung of each infected mouse was excised and
homogenized by bead beating in 1 ml sterile PBS/Protease in-
hibitor. 500 µl of lung homogenate was used for cytokine pro-
filing. Cytokines representing T-helper type 1 (Th1) (interleukin
[IL]-12p70, tumor necrosis factor [TNF]-α, interferon [IFN]-γ ),
T-helper type 17 (IL-17), and T-helper type 2 (Th2) (IL-4, IL-
5, IL-10) responses were measured using a customized Bio-Plex
ProTM Mouse Cytokine Th1/Th2 Assay kit (Biorad, San Fran-
cisco, CA, USA) with the BioPlex 200 platform according to
the manufacturer’s guidelines. Data were retrieved using BioPlex
Manager Software. The upper and lower limits of quantification
(ULOQ and LLOQ) were based on a standard curve. All val-
ues falling below the LLOQ were replaced with the midpoint
between zero and the LLOQ. Data were standardized by lung
weight and presented as picogram of cytokines per gram lung
tissue (pg/g).
In vivo virulence assay
The virulence assay was conducted independently from the day
7/day 14 experiment. Each of the eight selected isolates was inoc-
ulated intranasally into 10 A/J mice. Mice were monitored daily
until death, or loss of more than 15% body weight (impending
death), at which point they were euthanized by CO2 inhalation,
necropsied and had fungal burden in lung and brain determined.
Statistical analysis
GraphPad Prism version 5.04 for Windows (GraphPad Soft-
ware, San Diego, CA, USA; www.graphpad.com) was used for
data visualization and statistical analyses of fungal loads, cy-
tokine profiling, capsular/cell size, and survival proportions. The
Mann-Whitney U-test was used for comparing fungal load and
cytokine concentrations. Kaplan-Meier survival curves and the
log-rank test were used for survival analysis. Capsule/cell size
was compared using Welch’s t test. The Fligner-Killeen test of
variance homogeneity for analyzing variation in capsule/cell size
and Fisher exact test were performed using R software, version
3.2.4 (http://www.r-project.org). One-way analysis of variance
(ANOVA) with post hoc multiple comparison tests (Dunnett or
Bonferroni) was used to compare cytokine concentrations be-
tween individual isolates.
Results
C. neoformans in vitro virulence
We compared the capsule size, extracellular urease, phospho-
lipase production, melanin production, growth at 37°C, and
growth in pooled human CSF between the 15 ST5 and the 15
non-ST5 C. neoformans isolates. We observed no significant
genotype-specific differences between growth at 30°C (P = .10),
growth at 37°C (P = .23), ex vivo survival in CSF after 1 day
(P = .72), ex vivo survival in CSF after 3 days of exposure
(P = .77), extracellular urease activity, or phospholipase activity
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Table 2. Variability in in vitro capsule thickness and cell diameter
of Cryptococcus neoformans strains by Sequence Type (ST).
MLST group
Variable ST5 Non-ST5
Capsule Thickness (μm)
Mean* 2.64 2.01
95% CI 2.49–2.79 1.94–2.07
Range 0.01–9.56 0.02–6.16
Coefficient of Variation$ (%) 0.63 0.37
Cell diameter (μm)
Mean* 11.38 9.69
95% CI of Mean 10.96–11.79 9.52–9.87
Range 4.74–27.22 5.25–19.89
Coefficient of Variation$ (%) 0.41 0.20
*P < .0001, t-test with Welch’s correction.
$P < .0001, Fligner-Killeen test of homogeneity of variance.
(Fig. S1). ST5 C. neoformans cells developed significantly thicker
capsules during in vitro culture than non-ST5 isolates (Table 2).
Individual ST5 C. neoformans cells were also significantly larger
than non-ST5 cells (Fig. 1), and we observed significantly greater
variation in capsule size and cell diameter within ST5 cells than
non-ST5 cells (Fig. 1; P < .0001, Fligner-Killeen test). Notably, a
single organism (BMD1646), was clearly larger and with thicker
capsules than other isolates. However, the difference in capsule
thickness and cell diameter between STs remained statistically
significant even when this isolate was removed from analysis.
In vivomouse infections with ST5 and non-ST5
isolates
We hypothesized that a higher prevalence of ST5 infections in
apparently healthy hosts was associated with higher virulence.
Therefore, we challenged A/J with equivalent doses of represen-
tative isolates (five ST5 and three non-ST5; the individual in
vitro virulence phenotyping results for these eight isolates are
presented in supplementary Figures S2–S4). Contrary to our hy-
pothesis, we found that mice infected with ST5 organisms had
significantly longer survival times than mice infected with non-
ST5 organisms (P < .0001, Fig. 2A). However, there was signifi-
cant variability in the effect of individual organisms of the same
ST on survival (Fig. 2B). Specifically, two ST5 organisms (BK147
and BMD1646) were substantially attenuated in comparison to
Figure 1. In vitro induced capsule thickness and cell diameter of individual Cryptococcus neoformans strains from Vietnam: Cells were grown on DMEM
medium/5% CO2 and visually assessed by India ink staining. Images were taken for single cells measurement using ImageJ software. Capsule thickness is
obtained by subtracting cell body diameter from total cell diameter. AFLP-VNI-γ /MLST-ST5 strains expressed higher degree of variation in both capsule size
and cell diameter in vitro, which remains significant even when the outlier BMD1646 was removed from the analysis (P < .0001 for both capsule and cell size,
Fligner-Killeen test). Scattered plot represents single cells from an individual strain. Data for individual strains are presented as mean with error bars denoting
standard deviation. Strains selected for experiment in mice were indicated by asterisks.
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Figure 2. Kaplan-Meier survival curves for mice infected with either ST5 (n = 5) or non-ST5 (n = 3) Cryptococcus neoformans strains. 10 A/J mice were infected
per strain (five ST5 strains and three non-ST5 strains). Mice were monitored daily until the point of more than 15% weight loss or visible suffering and were
then sacrificed by CO2 inhalation. Mice infected with ST5 strains had statistically significantly longer survival times than those infected with non-ST5 strains
(P < .0001, Mantel-Cox log rank test) (A). Two ST5 strains, BK147 and BMD1646, were attenuated, suggesting high degree of heterogeneity within the ST5 cluster.
Mice infected with BK147 and BMD1646 survived for as long as 42 days postinfection, at which point the experiment was terminated and all infected mice
sacrificed (B).
Table 3. Tissue fungal burden in lung and brains of mice at days 7,
14, and at time of death by infecting MLST sequence type (ST).
Fungal burden (Mean log10 colony forming
units per gram of tissue) [95%CI]
Tissue ST5 Non-ST5 P value
Lung (Day 7) 4.96 [3.86–6.05] 7.07 [6.85–7.29]* <.001
Brain (Day 7) 0.81 [0.38–1.24] 1.59 [0.87–2.30] .054
Lung (Day 14) 5.48 [4.34–6.62] 8.00 [7.77–8.23]* <.0001
Brain (Day 14) 1.56 [0.81–2.31] 1.91 [1.12–2.69] .36
Lung (Death) 3.81 [3.05–4.57] 6.53 [6.30–6.76]* <.0001
Brain (Death) 2.90 [2.23– 3.56] 4.29 [3.90–4.68]* .01
*Mann-Whitney test.
other ST5 organisms; the mice infected with these organisms sur-
vived up to 40 days. However, differences in survival times be-
tween mice infected with ST5 and non-ST5 organisms remained
significant when these two isolates were removed from the anal-
ysis (P = .003; log-rank test).
The tissue-specific fungal burden data are shown in Table 3.
All organisms established lung infection and disseminated brain
infection as early as 7 days postinfection. Non-ST5 infections
resulted in higher fungal burdens in lung than ST5 infections at
all time-points (day 7, P < .001; day 14, P < .0001; and end
of the experiment, P < .0001 (Fig. 3). Again, these data were
not driven by the two apparently attenuated ST5 isolates as the
fungal loads associated with the ST5 infections were significantly
lower even when excluded from the analysis. The majority of
animals infected with the attenuated ST5 organisms (BMD1646
[4/5 mice] and BK147 [5/5 mice]) had low fungal burdens in the
lungs up to day 14 (Fig. 3). Fungal burdens in the brain were
higher in non-ST5 infected animals at all time points; however,
this difference was only statistically significant at the end of the
experiment (P = .054, P = .36, and P = .01; Mann-Whitney test
at days 7, 14, and point of impending death (time when 15%
body weight loss is observed).
ST5 C. neoformans isolates induce of TNF-α in the
lungs of infected mice
We next measured the cytokine concentrations in lung ho-
mogenates at days 7 and 14 postinfection (Fig. 4). The concen-
trations of TNF-α were significantly higher in lung homogenates
from mice infected with ST5 than non-ST5 infections (P = .01).
Of note, the highest day 7 lung TNF-α concentrations were as-
sociated with the ST5 organisms that were most attenuated in
the mouse survival model (BK147 and BMD1646). Correspond-
ingly, the lowest TNF-α concentrations were measured in the
most virulent ST5 isolate in the mouse model (BMD1338).
By day 14, the mean TNF-α concentrations in lung ho-
mogenates associated with the ST5 infections had declined from
3933.71 pg/g lung to 2802.36 pg/g lung (P < .001). Other
Th-1 cytokines (IL-12 and IFN-γ ), and IL-17, also decreased in
ST5-infected mice between days 7 and 14 (P < .001, P < .01,
and P = .02, respectively). This contrasted with the non-ST5
infections, in which the mean TNF-α levels had increased from
3256.25 pg/g to 6378.76 pg/g (P = .02) over this same period.
The high TNF-α concentration associated with non-ST5 infec-
tions at day 14 was driven by a single isolate - BMD1415. The
TNF-α concentrations in lung homogenates from mice infected
with this isolate were significantly higher than for infections
with any other isolate of any lineage (P < .001). There were no
statistically significant differences in TNF-α concentrations at
day 14 between lineages when this isolate was excluded from
the analysis. Similarly, the concentrations of these two cytokines
in BMD1415-infected mice was significantly higher than in mice
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Figure 3. Fungal burden in mouse lung and brain tissue at days 7, 14, and the point of impending death (mortality experiment) according to infecting genotype. In
vivo virulence (tissue fungal burden and mortality) was assessed in three independent mouse infection experiments. In the first two experiments, five A/J mice
were infected with each of the eight test C. neoformans isolate (five ST5 isolates and three non-ST5 isolates, total N = 40 mice in each experiment). All mice were
sacrificed at day 7 postinfection in the first experiment and at day 14 postinfection in the second experiment to assess in vivo fungal burden in mouse lung and
brain. Fungal burden in the lung and brain at either day 7 or day 14 for each isolate is presented in (A). In the last experiment, 10 A/J mice were infected with
each of the 8 test C. neoformans isolate (five ST5 isolates and three non-ST5 isolates, N = 80 mice in total) and monitored daily until the point when 15% of body
weight loss, a sign of distress and impending death, was evident. Fungal burden in lung and brain at point of death was again assessed as before. Here, for each
strain, five mice were randomly selected from the 10 test mice for fungal burden investigation. The pooled fungal burden in non-ST5 infections was higher than
in ST5 infections in both lung tissue at all time points, and in brain tissue at the point of sacrifice (B). (For P values see text). Boxplots (Tukey method) describe
the median and interquartile range, the whiskers demarcate the largest or smallest values that were not outliers (black dots); outliers are defined as more than
1.5 times the interquartile range from the nearest quartile.
infected with any other isolate (P < .001). However, the IL-12
concentrations declined in non-ST5-infected mice, including
BMD1415, between days 7 and 14 (4 fold decrease, P < .0001)
(Fig. 5).
We measured the TNF-α:IL-10 ratio as a proxy for the rela-
tionship between a Th-1 and a Th-2 response.25 From day 7 to
day 14 days postinfection, the TNF-α:IL-10 ratio decreased by
a factor of 0.78 in mice infected with ST5 isolates, while those
infected with non-ST5 strains exhibited an increase in the ra-
tio of 1.25-fold. However, when BMD1415 (ST4) was excluded
from the analysis the TNF-α/IL-10 ratio in non-ST5 infected
mice decreased by a factor of 0.67. By day 14 we detected el-
evated concentrations of IL-17 and IFN-γ in non-ST5 infected
mice (5-fold and 17-fold increments, respectively; Table 4) but
not in ST5 infected mice. Again, this effect was largely associated
with BMD1415, since the concentrations of IL-17 and IFN-γ in-
duced by this isolate at day 14 were significantly higher than for
all others (P < .001).
Histopathological examination
Histological examination of infected lung tissue revealed evi-
dence of inflammation, hemorrhage, edema, and necrosis in most
cases. These changes were generally greater by day 14 in com-
parison to day 7. There were no clear differences in histological
scores between ST, other than with BMD1646 (ST5), which gen-
erated only mild inflammation with no evidence of necrosis or
hemorrhage (Fig. S5). PAS staining revealed extensive perivascu-
lar infiltration of leukocytes in mice tissue associated with both
infecting genotypes (BMD1338-ST5 and BMD1415-ST4, Fig. 6).
Extensive in vivo encapsulation of C. neoformans var. grubii in
mouse lung was visualized using mucicarmine staining (Fig. 7).
We did not formally assess yeast capsule and cell size in the his-
tological specimens and thus were unable to confirm the in vitro
finding that ST5 organisms had larger capsule and cell sizes.
Discussion
Most cases of cryptococcal meningitis in HIV uninfected, ap-
parently immunocompetent, patients in Vietnam and East Asia
are due to C. neoformans strains of multi-locus sequence type 5
(ST5).9,10,12,17,26–28 This phenomenon could be explained either
by ST5 strains being intrinsically more pathogenic or due to
unidentified lineage–specific host immune defects or exposures.
It is unlikely that the high prevalence of ST5 infection observed
in HIV-uninfected patients is explained by a significantly greater
D
ow
nloaded from
 https://academ
ic.oup.com
/m
m
y/advance-article-abstract/doi/10.1093/m
m
y/m
yaa013/5810715 by guest on 07 M
ay 2020
8 Medical Mycology, 2020, Vol. 00, No. 00
Figure 4. Genotype-specific cytokine concentrations from lung homogenate of A/J mice at 7 and 14 days postinfection with 5 × 104 C. neoformans cells/mouse.
Five mice were infected with each strain from each genotype at each time points. ST5 strains induced significantly higher levels of TNF-α at day 7, suggesting
an earlier and more profound initial inflammatory response in infected mice. By day 14 mice infected with non-ST5 strains have higher levels proinflammatory
cytokines, probably a result of ST5 yeasts being cleared more rapidly from infected mice. The horizontal line within the box indicates the median; boundaries of
the box indicate the 25th and 75th percentiles, and the whiskers indicate the highest and lowest values of the results; outliers are denoted as black dots (Tukey
method). Data are standardized as picograms of cytokine per gram lung tissue. Asterisks indicate statistically significant differences (Mann-Whitney test).
Figure 5. Genotype-specific changes in cytokine concentrations from lung homogenate of A/J mice infected with C. neoformans between day 7 and day 14
postinfection. Box and whisker plots (Tukey method) compare levels of each cytokine between day 7 and day 14 for each genotype. Data are standardized as
picograms of cytokine per gram lung tissue. Asterisks indicate statistically significant differences (Mann-Whitney test).
prevalence of the lineage in the environment since it causes
only 35% of cases in HIV-infected patients within the same
geographical area.9 Furthermore, data from China suggest that
ST5 strains are significantly less prevalent in the environment,
making up only 5% of isolates recovered in a recent study.29 We
investigated the first hypothesis by comparing previously identi-
fied in vitro virulence-associated phenotypes, along with murine
in vivo virulence and immune responses, between lineages. All
isolates were derived from HIV-infected or uninfected Viet-
namese patients with cryptococcal meningitis. The comparison
by MLST defined lineage is appropriate because ST5 is a coher-
ent and distinct group, whole genome sequence data revealing
that there are few intra-lineage genomic variations between
ST5 strains.17 More recent phylogenetic analysis using whole
genome sequencing of a larger collection of clinical isolates from
Vietnam, including the eight strains tested in the mouse model,
has established that the MLST ST5 and ST4/ST6/306 groups
are genetically distinct lineages (VNIa-5 and VNIa-4, respec-
tively).15 It is unlikely that any phenotypic variations among
ST5 isolates are primarily attributable to subtle intralineage
genomic variations since phenotypic and genotypic diversity are
not tightly coupled in C. neoformans var. grubii.30 Due to the
fact that ST5 has been shown to be consistently associated with
the clinical phenotype of interest (infection in HIV-uninfected
patients), and that strains from HIV-uninfected patients are
dispersed throughout the VNIa-5 cluster, we believe the ability
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Table 4. Cytokine concentrations from lung homogenate of infected mice at day 7 and day 14 post-infection according to infecting Cryp-
tococcus neoformansMLST group.
Mean cytokine concentration (pg per gram of lung tissue)
[95%CI]
Cytokine ST5 Non-ST5
*P value (ST5
vs non-ST5)
Day 7
Th-1 IL-12 853.12 822.87 .30
[750.50–955.80] [608.90–1037.00]
IFN-γ 136.02 150.59 .97
[115.00–157.00] [105.80–195.30]
TNF-α 3933.71 3256.25 .01
[3486.00–4381.00] [2630.00–3882.00]
Th-2 IL-4 230.79 253.24 .92
[162.80–298.80] [11.60–349.90]
IL-5 561.05 459.85 .91
[369.00–753.10] [344.40–575.40]
IL-10 145.01 139.99 .68
[128.20–161.80] [119.30–160.70]
Th-17 IL-17 268.48 243.41 .24
[155.90–381.00] [165.60–321.20]
TNF-α/IL-10 ratio 27.13 23.26 ND
Day 14
Th-1 IL-12 547.84 213.72 <.01
[412.40–683.30] [120.50–306.90]
IFN-γ 91.2 1760.67 .09
[57.25–125.20] [166.50–3355.00]
TNF-α 2802.36 6378.76 <.01
[2385.00–3220.00] [3374.00–9384.00]
Th-2 IL-4 1154.72 800.35 .60
[673.50–636.00] [604.70–996.00]
IL-5 294.6 347.55 .15
[170.40–418.80] [279.20–415.90]
IL-10 132.76 220.15 .01
[102.10–163.40] [172.40–267.90]
Th-17 IL-17 175.75 1012.49 .01
[65.54–286.00] [459.20–1566.00]
TNF-α/IL-10 ratio 21.11 28.97 ND
*Mann-Whitney test. ND = not done.
to infect apparently immunocompetent hosts is common to all
ST5 isolates. All comparisons of ST versus non-ST5 in this study
were thus essentially VNIa-5 versus VNIa-4.
We found that isolates from all STs were able to grow in ex
vivo human CSF and at 37°C - essential characteristics for es-
tablishing human CNS infection. While these qualities would be
needed for disease in both HIV infected and immunocompetent
patients, it might have been expected that ST5 strains would
grow more rapidly in these conditions. The lack of ST-specific
differences in these phenotypes suggests that the ability to estab-
lish disease in HIV-uninfected/immunocompetent patients is not
driven by simple adaptations to these conditions.
Notably, ST5 cells were significantly larger than non-ST5
cells, had thicker capsules in vitro, and had more within
lineage variation in these characteristics. Capsule size and com-
position are known to vary during infection and under specific
stress conditions,31,32 influencing macrophage phagocytosis and
modulating host immune response,32–35 and in human disease,
ex vivo capsule size has been associated with higher intracra-
nial pressures, slower yeast clearance and attenuated inflamma-
tion.34While we did not formally measure yeast cell or capsule
size in our in vivo experiments, mucicarmine staining was sug-
gestive that capsules were indeed larger during mouse infection.
It is possible that the ability of ST5 strains to cause infections
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Figure 6. Periodic acid Schiff (PAS) staining of pulmonary tissue frommice infected with BMD1338 and BMD1415 on days 7 and 14. The two strains represent ST5
and non-ST5, respectively. A/J mice were inoculated intranasally with 5 × 104 yeast cells. Lung specimens were harvested at days 7 and 14 for histopathological
examination. Photomicrographs were obtained at 200× magnification; the scale bar represents 215 μm). (A–B): Lung sections from mice infected with BMD1338
(VNI-γ /ST5) at day 7 and day 14, respectively. (C–D): Lung sections from mice infected with BMD1415 (VNI-δ/ST4) at day 7 and day 14, respectively. Perivascular
infiltration (red arrows) and necrosis are more marked by day 14 for both strains. Encapsulated yeasts (yellow arrows), notable for the larger cell size and capsule
thickness of BMD 1338 compared with BMD1415.
in immunocompetent patients is a function of increased respon-
siveness to capsule-inducing conditions. Further investigation of
genotype-specific characteristics of in vitro and in vivo capsu-
lar polysaccharide production, composition, and morphology,
may elucidate a specific role in ST5-associated pathogenesis. Of
note, cryptococcal virulence factors frequently have additional
metabolic functions; the increased cell and capsule size seen in
ST5 isolates may be a side effect of other processes involving
capsular-biosynthesis genes (e.g., carbon source sensing, sugar
transport and spore formation).36,37.
Our data indicate that phenotypic heterogeneity may be a
hallmark characteristic of the ST5 lineage. Heterogeneity is a
desirable trait for microbial populations under selection pres-
sure allowing the exploitation of, and survival, in novel niches.38
Chow et al. 39 has previously reported that ST5 C. neofor-
mans var. grubii possesses unique genomic features that may
drive niche adaptation. We speculate that the phenotypic het-
erogeneity associated with strains from the ST5 lineage is a
strategy that facilitates successful colonization of novel en-
vironmental niches, including the exploitation of infrequent
specific human immune deficits. Morphological variation in-
cluding cell size, capsule size and cell shape has also been
associated with different patient clinical symptoms, suggest-
ing greater capacity for pathogenicity, immune evasion, and
pathogenesis.40
However, paradoxically, we found no evidence that ST5
isolates have greater virulence in the mouse model. There are
several possible explanations. First, virulence in mice is variable
depending onmouse breed andmay not accurately reflect the im-
munological heterogeneity of the human population.41 Second,
yeasts with different pathogenic potentials, associated with their
isolation from different sources (i.e., clinical vs environmental,
immunocompromised vs immunocompetent patients) may have
the same or paradoxical pathogenic potential in experimental
animal models. An example is Cryptococcus gattii, which is
associated with infection in immunocompetent patients and
therefore is considered to be more fit in the human host than C.
neoformans. However, the hypervirulent C. gattii strain R265,
responsible for the on-going Vancouver outbreak, has similar
virulence in both C57BL/6 and A/J mice to the C. neoformans
H99 strain, which was derived from a patient with Hodgkin’s
disease on chemotherapy.42 Third, the A/J mouse breed is not
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Figure 7. Mucicarmine staining of capsular material in paraffin-embedded
mice pulmonary tissue. Uninflated lung specimens were harvested frommice
as described in themethods.Mucicarmine stainingwas performed to visualize
the cryptococcal capsule. Photomicrographs were captured at 400× magnifi-
cation with scale bar indicating 55 µm. Capsular polysaccharide is stained pink
(indicated by blue arrows), demonstrating diffuse localization consistent with
extensive capsule production by yeasts in the alveolar space.
immunologically intact; it may be an imperfect model of infec-
tion for immunocompetent hosts.43 Rather, A/J mice may be a
better model of disease in immunosuppressed patients, as they
are highly susceptible to cryptococcal disease, and the patterns
of cytokine expression in mice with disseminated cryptococcosis
are similar to those seen in HIV-infected patients with CM.44
Consistent with this, we could not detect clinical differences in
disease course or outcome between HIV patients infected with
ST5 versus other strains in Vietnam.17 Models that better mimic
infection in immunocompetent hosts are needed.
We did identify lineage specific differences in immune re-
sponse in the mouse model. Previous research has suggested
that a Th1 type immune response, defined by the TNF-α/IL-10
ratio, is protective, and a Th2 response is associated with poor
outcomes.45,46 We found no evidence of genotype-specific differ-
ences in TNF-α/IL-10 ratios by lineage in the murine infection
model. Rather, we found higher initial (day 7) TNF-α concentra-
tions in mice infected with ST5 isolates, suggesting this genotype
elicits a more intense initial inflammatory response. Previous
studies have suggested that capsule components, or cryptococcal
cells themselves, have a dose-dependent ability to stimulate
TNF-α production by various immune effector cells.47,48 The
more robust initial inflammatory response we observed may
have been due to the ST5 capsular phenotype. Previously, it has
been suggested that the ability of C. gattii to cause disease in ap-
parently immunocompetent patients is because it induces a less
severe inflammatory response compared with other cryptococcal
species.42 The robust initial inflammatory responses seen in our
murine infection experiments are not consistent with this being
the mechanism underlying the ability of ST5 C. neoformans var.
grubii organisms to cause disease in the immunocompetent.
In vivo controlled infection studies in mice, including ours,
commonly employ the classic definition of pathogenicity as
the microbe’s capability to cause disease in a susceptible host,
whereas virulence corresponds to the severity of the ensuing
pathology.49 Using the same infective dose for all strains we
failed to demonstrate that ST5 strains had greater virulence. The
difference we observe in prevalence of different lineages in im-
munocompetent and immunosuppressed humans may actually
represent specific differences in pathogenicity—the ability of the
organisms to colonize the host and establish infection. We could
not assess this with our experimental system.
In summary, our cohort of ST5 Cryptococcus isolates
displayed two notable phenotypes. First, despite their well-
documented ability to cause disease in HIV-uninfected humans,
they appeared to be less virulent in a murine model than the
other sequence types, as demonstrated by reduced fungal bur-
dens in tissue and prolonged mouse survival. Second, ST5 strains
had larger capsules and cell sizes than the other genotypes,
and greater variability in this phenotype throughout the lineage.
These data lead us to the following conclusions. First, clinical
isolates, which have by their nature already undergone selec-
tion within the human host, can possess wide variability in the
expression of virulence phenotypes within a single lineage. Sec-
ond, the use of host risk factors and immune phenotypes to de-
rive an understanding of the factors that drive the pathogenicity
of Cryptococcus neoformans may be more complex than antic-
ipated. Associations may be difficult to make due to the rele-
vance of the particular in vitro phenotypes, the animal models
used, within strain heterogeneity, and population substructure.
Moreover, there may be heterogeneity in the immune response
of apparently immunocompetent patients, which selects particu-
lar subcohorts of isolates of the same lineage. Laboratory pheno-
typing of larger numbers of clinical isolates is needed to define
the lineage-specific differences that determine different human
disease phenotypes.
Finally, it is possible that the categorization of strains into spe-
cific clades with limited genetic information such as MLST may
lack precision to understand the relative fitness of specific strains
in the human host. It is likely that whole genome sequencing will
provide better mapping of the relationships between strains and
virulence.
In conclusion, in this study, we demonstrated genotype-
specific differences in in vitro and in vivo virulence phenotypes
between C. neoformans var. grubii strains isolated from host
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with different immune status. However, there was also signifi-
cant variation among strains isolated from apparently immuno-
competent patients in specific in vitro and in vivo phenotypes
tested. This higher rate of phenotypic variation may represent an
evolutionary strategy for C. neoformans var. grubii to take ad-
vantage of novel niches and contribute to their ability to in-
fect apparently immunocompetent hosts, despite generally being
less virulent in a mammalian animal model. Furthering the un-
derstanding of the pathogenesis of cryptococcal meningitis will
require investigation of large numbers of strains with associ-
ated robust clinical information, and the development of high
throughput laboratory phenotypic studies that have clinical rel-
evance in humans.
Supplementary material
Supplementary data are available at MMYCOL online.
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